Lite Strategy (LITS)
Market Price (6/25/2026): $0.8904 | Market Cap: $31.8 MilSector: Health Care | Industry: Biotechnology
Lite Strategy (LITS)
Market Price (6/25/2026): $0.8904Market Cap: $31.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -31% | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -137% | Penny stockMkt Price is 0.9 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -12 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -200% Key risksLITS key risks include [1] significant financial exposure to the market price of Litecoin (LTC) due to its core treasury strategy of holding the digital currency as its primary reserve asset. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -31% |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -137% |
| Penny stockMkt Price is 0.9 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -12 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -200% |
| Key risksLITS key risks include [1] significant financial exposure to the market price of Litecoin (LTC) due to its core treasury strategy of holding the digital currency as its primary reserve asset. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/22/2026
Lite Strategy (LITS) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. Continued Unprofitability and Declining Earnings. Lite Strategy reported a significant loss of -$23.7 million for fiscal Q3 2026, which ended March 31, 2026, representing a 23.1% decrease from the prior quarter. For the trailing twelve months ending March 31, 2026, the company's earnings totaled -$60.8 million, indicating persistent financial underperformance.
2. Decline in Litecoin (LTC) Value. As a company whose primary treasury asset is Litecoin, Lite Strategy's stock movement is closely tied to the cryptocurrency's performance. The value of Litecoin (LTC) experienced an approximate 14.33% decline over one month as of May 13, 2026, directly impacting the perceived value of Lite Strategy's holdings and contributing to the stock's downturn.
Show more
Lite Strategy (LITS) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. Continued Unprofitability and Declining Earnings. Lite Strategy reported a significant loss of -$23.7 million for fiscal Q3 2026, which ended March 31, 2026, representing a 23.1% decrease from the prior quarter. For the trailing twelve months ending March 31, 2026, the company's earnings totaled -$60.8 million, indicating persistent financial underperformance.
2. Decline in Litecoin (LTC) Value. As a company whose primary treasury asset is Litecoin, Lite Strategy's stock movement is closely tied to the cryptocurrency's performance. The value of Litecoin (LTC) experienced an approximate 14.33% decline over one month as of May 13, 2026, directly impacting the perceived value of Lite Strategy's holdings and contributing to the stock's downturn.
Show more
Updated on 6/22/2026
Lite Strategy (LITS) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. Continued Unprofitability and Declining Earnings. Lite Strategy reported a significant loss of -$23.7 million for fiscal Q3 2026, which ended March 31, 2026, representing a 23.1% decrease from the prior quarter. For the trailing twelve months ending March 31, 2026, the company's earnings totaled -$60.8 million, indicating persistent financial underperformance.
2. Decline in Litecoin (LTC) Value. As a company whose primary treasury asset is Litecoin, Lite Strategy's stock movement is closely tied to the cryptocurrency's performance. The value of Litecoin (LTC) experienced an approximate 14.33% decline over one month as of May 13, 2026, directly impacting the perceived value of Lite Strategy's holdings and contributing to the stock's downturn.
3. Persistent Discount to Treasury Net Asset Value (NAV). Lite Strategy has traded at a notable discount to its underlying asset value. As of May 13, 2026, the company's Basic mNAV (Enterprise Value divided by LITS Treasury NAV) stood at 0.51x, with a market capitalization of $28.17 million against a Treasury NAV of $40.31 million. This indicates investor skepticism regarding the company's ability to fully realize the value of its Litecoin holdings.
4. Negative Market Reaction to Strategic Investment. Lite Strategy's announcement in June 2026 of a $1.0 million lead strategic investment in LitVM, a zero-knowledge Layer 2 platform on Litecoin, was met with a negative market response, leading to a 6.97% decline in the stock. This suggests investor apprehension regarding the company's capital allocation choices or the potential returns from such ventures.
Show less
Lite Strategy (LITS) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. Continued Unprofitability and Declining Earnings. Lite Strategy reported a significant loss of -$23.7 million for fiscal Q3 2026, which ended March 31, 2026, representing a 23.1% decrease from the prior quarter. For the trailing twelve months ending March 31, 2026, the company's earnings totaled -$60.8 million, indicating persistent financial underperformance.
2. Decline in Litecoin (LTC) Value. As a company whose primary treasury asset is Litecoin, Lite Strategy's stock movement is closely tied to the cryptocurrency's performance. The value of Litecoin (LTC) experienced an approximate 14.33% decline over one month as of May 13, 2026, directly impacting the perceived value of Lite Strategy's holdings and contributing to the stock's downturn.
3. Persistent Discount to Treasury Net Asset Value (NAV). Lite Strategy has traded at a notable discount to its underlying asset value. As of May 13, 2026, the company's Basic mNAV (Enterprise Value divided by LITS Treasury NAV) stood at 0.51x, with a market capitalization of $28.17 million against a Treasury NAV of $40.31 million. This indicates investor skepticism regarding the company's ability to fully realize the value of its Litecoin holdings.
4. Negative Market Reaction to Strategic Investment. Lite Strategy's announcement in June 2026 of a $1.0 million lead strategic investment in LitVM, a zero-knowledge Layer 2 platform on Litecoin, was met with a negative market response, leading to a 6.97% decline in the stock. This suggests investor apprehension regarding the company's capital allocation choices or the potential returns from such ventures.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -22.7% change in LITS stock from 2/28/2026 to 6/24/2026 was primarily driven by a 4.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6242026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.13 | 0.87 | -22.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 37 | 36 | 4.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/24/2026| Return | Correlation | |
|---|---|---|
| LITS | -22.7% | |
| Market (SPY) | 7.2% | 37.1% |
| Sector (XLV) | -3.9% | 23.1% |
Fundamental Drivers
The -53.8% change in LITS stock from 11/30/2025 to 6/24/2026 was primarily driven by a -17.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6242026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.89 | 0.87 | -53.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 29 | 36 | -17.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/24/2026| Return | Correlation | |
|---|---|---|
| LITS | -53.8% | |
| Market (SPY) | 7.9% | 40.4% |
| Sector (XLV) | -1.9% | 15.0% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2025 to 6/24/2026| Return | Correlation | |
|---|---|---|
| LITS | ||
| Market (SPY) | 25.8% | 38.5% |
| Sector (XLV) | 17.7% | 12.9% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/24/2026| Return | Correlation | |
|---|---|---|
| LITS | ||
| Market (SPY) | 82.4% | 38.5% |
| Sector (XLV) | 26.1% | 12.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LITS Return | - | - | - | - | -55% | -33% | -70% |
| Peers Return | 70% | -79% | 357% | 109% | -19% | 5% | 197% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 96% |
Monthly Win Rates [3] | |||||||
| LITS Win Rate | - | - | - | - | 0% | 17% | |
| Peers Win Rate | 50% | 29% | 71% | 52% | 52% | 43% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| LITS Max Drawdown | - | - | - | - | - | -52% | |
| Peers Max Drawdown | -55% | -82% | -43% | -48% | -56% | -42% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MSTR, GLXY, COIN, TSLA, MARA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/24/2026 (YTD)
How Low Can It Go
LITS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
LITS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Lite Strategy (LITS)
Lite Strategy (LITS) is a late-stage pharmaceutical company primarily focused on the discovery, development, and commercialization of innovative therapies for the treatment of various cancers. Based in San Diego, California, the company aims to address significant unmet medical needs in oncology by advancing a pipeline of novel drug candidates.
The company's main products are a portfolio of investigational cancer drugs. Its lead candidate, Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in Phase III clinical trials for relapsed/refractory follicular lymphoma and Phase Ib for B-cell malignancies. Other key pipeline assets include Voruciclib, an oral cyclin-dependent kinase 9 inhibitor in Phase Ib for acute myeloid leukemia and B-cell malignancies; ME-344, a mitochondrial inhibitor in Phase I for human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral histone deacetylase inhibitor in Phase II for myelodysplastic syndrome.
Lite Strategy primarily serves the oncology market, targeting patients diagnosed with a range of cancers such as follicular lymphoma, acute myeloid leukemia, B-cell malignancies, certain breast cancers, and myelodysplastic syndrome. To facilitate its development and commercialization efforts, the company has established strategic collaborations and licensing agreements with global pharmaceutical partners, including Kyowa Kirin Company, BeiGene, Ltd., and Helsinn Healthcare SA.
AI Analysis | Feedback
- A small Genentech focused on experimental cancer drugs in clinical trials.
- The cancer drug R&D lab of a Pfizer or Bristol Myers Squibb, operating independently.
AI Analysis | Feedback
- Zandelisib: An oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase III clinical trial for follicular lymphoma and Phase Ib for B-cell malignancies.
- Voruciclib: An oral cyclin-dependent kinase 9 inhibitor in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
- ME-344: A mitochondrial inhibitor targeting the oxidative phosphorylation complex, which is in Phase I clinical trial for HER2-negative breast cancer.
- Pracinostat: An oral histone deacetylase inhibitor in Phase II clinical trial for patients with myelodysplastic syndrome.
AI Analysis | Feedback
The company, MEI Pharma, Inc., which trades under the symbol LITS for the purpose of this request, primarily sells its intellectual property and collaborates on the development and commercialization of its therapies with other pharmaceutical and biotechnology companies. Therefore, its major "customers" are its partner companies.
Here are the names of its major customer/partner companies, along with their symbols if they are public:
- Kyowa Kirin Company (TYO: 4151)
- BeiGene, Ltd. (NASDAQ: BGNE, HKEX: 6160)
- Helsinn Healthcare SA
- Presage Biosciences, Inc.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are the key risks to Lite Strategy (LITS):
- Market Volatility and Impairment Charges Related to Litecoin (LTC) Holdings: Lite Strategy's business model relies on adopting Litecoin (LTC) as its primary reserve asset, which exposes the company to significant market volatility and fluctuations in cryptocurrency prices. A decrease in the market price of LTC could lead to substantial impairment charges, directly impacting the company's financial stability.
- Government Regulation and Legal Uncertainties Regarding Cryptocurrencies: The company faces risks due to the uncertain and evolving landscape of government regulation concerning cryptocurrencies. Unfavorable regulatory changes could adversely affect Lite Strategy's digital asset treasury management business model and its acceptance in the market.
- Risks Inherent in Clinical-Stage Pharmaceutical Development: Despite its pivot to digital assets, Lite Strategy continues its operations as a clinical-stage pharmaceutical company. This exposes the company to inherent risks associated with drug development, including the potential for clinical trial failures, delays in the regulatory approval process for its drug candidates like voruciclib and zandelisib, and the overall success of bringing novel therapies to market.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are the addressable markets for Lite Strategy's (LITS) main pharmaceutical products:
- Zandelisib (relapsed/refractory follicular lymphoma and B-cell malignancies)
- For relapsed/refractory follicular lymphoma, the global market for follicular lymphoma drugs was valued at approximately USD 1.8 billion in 2024 and is projected to reach USD 3.05 billion by 2032. In the 7MM (United States, EU4, and UK, and Japan), the market size is expected to grow from USD 1,702 million in 2025 to USD 3,081 million in 2036. The United States accounted for the largest market share in the 7MM, with approximately USD 1,000 million in 2024.
- For B-cell malignancies (B-cell lymphoma), the global market size was approximately USD 5.08 billion in 2024 and is projected to increase to USD 10 billion by 2034. Across the top 7 markets (US, EU4, UK, and Japan), the B-cell lymphoma market reached a value of USD 5.0 billion in 2024, with projections to reach USD 9.2 billion by 2035. North America dominated the B-cell lymphoma market with a 39% share in 2024, and the U.S. market alone was valued at USD 1.39 billion in 2024, with projections to reach around USD 2.78 billion by 2034.
- Voruciclib (acute myeloid leukemia and B-cell malignancies)
- For acute myeloid leukemia (AML), the global treatment market size was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. Other estimates place the global AML treatment market at USD 3.87 billion in 2025, growing to USD 10.64 billion by 2035. North America held the largest share of the global AML treatment market at 37.6% in 2024, with the U.S. market being the dominant segment within North America, accounting for 90.9% of that share.
- The market size for B-cell malignancies is as listed above.
- ME-344 (human epidermal growth factor receptor 2 negative breast cancer)
- The global market for HER2-negative breast cancer was valued at approximately USD 14.4 billion in 2024 and is projected to reach USD 21.5 billion by 2030. Another estimate indicates the market size at USD 15.03 billion in 2024, expected to reach USD 23.32 billion by 2029. North America is the largest market for HER2-negative breast cancer treatments, accounting for approximately 45% of the global market share, with the U.S. being the primary market player.
- Pracinostat (myelodysplastic syndrome)
- The global myelodysplastic syndrome (MDS) drugs market size was estimated at USD 2.88 billion in 2023 and is projected to reach USD 5.28 billion by 2030. Another report estimates the global myelodysplastic syndrome drugs market size was valued at USD 4.55 billion in 2024 and is anticipated to reach approximately USD 11.17 billion by 2034. The 7MM (US, EU4, UK, and Japan) market size for MDS in 2023 was more than USD 2,800 million, with the U.S. holding the largest share, estimated at nearly USD 2,000 million in 2023. North America's myelodysplastic syndromes drugs market accounted for a 36% revenue share in 2024.
AI Analysis | Feedback
Lite Strategy, Inc. (LITS), formerly known as MEI Pharma, Inc., has pivoted its business model to include both clinical-stage pharmaceutical development and digital asset treasury management. Over the next 2-3 years, several key drivers are expected to contribute to its future revenue growth:
- Advancement and Commercialization of Oncology Drug Candidates: Lite Strategy continues to focus on the development of novel cancer therapies. A significant driver of future revenue growth is the successful progression and potential commercialization of its late-stage drug candidates, particularly Zandelisib and Voruciclib. Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in Phase III clinical trials for relapsed/refractory follicular lymphoma, while Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is in Phase Ib for acute myeloid leukemia and B-cell malignancies. Positive clinical trial results and subsequent market approvals would generate substantial revenue through product sales.
- Appreciation of Litecoin (LTC) Treasury Holdings: In September 2025, Lite Strategy expanded its business model to include digital asset treasury management, adopting Litecoin (LTC) as its primary reserve asset. The company aims to increase LTC exposure for its shareholders, positioning itself as the first U.S.-listed public company to do so. Growth in the market value of its substantial Litecoin holdings, driven by the overall performance of the digital asset, is anticipated to be a significant driver of financial performance and contribute to overall shareholder value.
- Strategic Digital Asset Management Initiatives: Beyond simply holding Litecoin, Lite Strategy's focus on "institutional-grade digital asset treasury strategies" suggests potential for further revenue generation. This could involve exploring advanced digital asset management activities such as staking, lending, or other yield-generating strategies that leverage its Litecoin reserves, thereby creating new revenue streams or financial gains for the company.
- Expansion of Strategic Partnerships and Collaborations: The company has a history of strategic alliances in its pharmaceutical segment (e.g., with Kyowa Kirin Company, BeiGene, Ltd., Helsinn Healthcare SA, and Presage Biosciences, Inc.). [BACKGROUND] Furthermore, it has established partnerships for its digital asset strategy, including advisory support from GSR and the involvement of Charlie Lee, the creator of Litecoin, on its board. New or expanded collaborations in either the pharmaceutical space (e.g., for drug development, licensing, or commercialization) or the digital asset sector could lead to milestone payments, licensing fees, or joint ventures that drive future revenue growth.
AI Analysis | Feedback
Share Repurchases
- Lite Strategy, Inc. authorized a share repurchase program for up to $25 million, announced in October 2025.
- The program became effective immediately, allowing for purchases in the open market or through negotiated transactions.
- Proceeds from active treasury operations, specifically a covered call options program that generated approximately $600,000 in gross premiums in fiscal Q2 2026 (ending December 31, 2025), are being utilized to fund the share repurchase program.
Share Issuance
- In July 2025, MEI Pharma, Inc. (prior to its rebranding as Lite Strategy, Inc.) completed a private placement, selling 29,239,767 shares of common stock at $3.42 per share, generating approximately $100 million in gross proceeds.
- The company also filed to sell 25.3 million shares of common stock for holders.
Inbound Investments
- MEI Pharma, Inc. secured approximately $100 million in a private placement in July 2025, which was intended to fund its Litecoin Treasury Strategy.
Outbound Investments
- In August 2025, MEI Pharma acquired 929,548 Litecoin (LTC) tokens at an average price of $107.58, establishing a treasury valued at $110.4 million as part of its new digital asset treasury management strategy.
- Lite Strategy sold its clinical asset ME-344 (rebranded as WE-868) to Aardvark Therapeutics.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 61.35 |
| Mkt Cap | 18.5 |
| Rev LTM | 3,714 |
| Op Inc LTM | 359 |
| FCF LTM | -647 |
| FCF 3Y Avg | -375 |
| CFO LTM | -31 |
| CFO 3Y Avg | -37 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.8% |
| Rev Chg 3Y Avg | 20.8% |
| Rev Chg Q | -18.4% |
| QoQ Delta Rev Chg LTM | -4.3% |
| Op Inc Chg LTM | 7.0% |
| Op Inc Chg 3Y Avg | -12.1% |
| Op Mgn LTM | 1.6% |
| Op Mgn 3Y Avg | 0.8% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | -1.0% |
| CFO/Rev 3Y Avg | -0.4% |
| FCF/Rev LTM | -3.5% |
| FCF/Rev 3Y Avg | -1.3% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development of pharmaceutical products | 0 | 65 | 49 | 41 | 35 |
| Total | 0 | 65 | 49 | 41 | 35 |
| $ Mil | 2008 |
|---|---|
| USA | -0 |
| Australia | -12 |
| Total | -12 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Development of pharmaceutical products | -16 | 18 |
| Total | -16 | 18 |
| $ Mil | 2016 | 2008 |
|---|---|---|
| Development of pharmaceutical products | 47 | |
| Australia | 3 | |
| USA | 17 | |
| Total | 47 | 20 |
Price Behavior
null
LITS Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.06 | 2.07 | 2.08 | 2.70 | 0.03 | 0.02 |
| Up Beta | 5.55 | 1.78 | 3.22 | 3.32 | -0.29 | -0.05 |
| Down Beta | -0.61 | 1.62 | 0.46 | 2.52 | -0.93 | -0.74 |
| Up Capture | 72% | 62% | 144% | 152% | 97% | 9% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 16 | 25 | 48 | 74 | 74 |
| Down Capture | 621% | 517% | 245% | 256% | 192% | 97% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 21 | 31 | 66 | 93 | 93 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LITS | |
|---|---|---|---|---|
| LITS | -70.3% | 81.4% | -1.56 | - |
| Sector ETF (XLV) | 17.6% | 15.1% | 0.87 | 12.9% |
| Equity (SPY) | 23.3% | 12.5% | 1.40 | 38.5% |
| Gold (GLD) | 17.7% | 27.7% | 0.57 | 13.8% |
| Commodities (DBC) | 18.2% | 18.6% | 0.76 | 2.4% |
| Real Estate (VNQ) | 11.6% | 13.8% | 0.56 | 15.7% |
| Bitcoin (BTCUSD) | -40.6% | 42.4% | -1.11 | 57.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LITS | |
|---|---|---|---|---|
| LITS | -21.5% | 81.4% | -1.56 | - |
| Sector ETF (XLV) | 6.0% | 14.8% | 0.22 | 12.9% |
| Equity (SPY) | 13.2% | 17.1% | 0.60 | 38.5% |
| Gold (GLD) | 16.4% | 18.3% | 0.73 | 13.8% |
| Commodities (DBC) | 6.9% | 19.5% | 0.26 | 2.4% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.04 | 15.7% |
| Bitcoin (BTCUSD) | 10.4% | 54.1% | 0.39 | 57.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LITS | |
|---|---|---|---|---|
| LITS | -11.4% | 81.4% | -1.56 | - |
| Sector ETF (XLV) | 9.8% | 16.6% | 0.48 | 12.9% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 38.5% |
| Gold (GLD) | 11.5% | 16.1% | 0.59 | 13.8% |
| Commodities (DBC) | 5.7% | 18.0% | 0.24 | 2.4% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 15.7% |
| Bitcoin (BTCUSD) | 57.2% | 66.5% | 0.97 | 57.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/26/2025 | 10-K |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/19/2024 | 10-K |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 09/26/2023 | 10-K |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 02/09/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/08/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/26/2025 | 10-K |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/19/2024 | 10-K |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 09/26/2023 | 10-K |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 02/09/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/08/2022 | 10-K |
| 03/31/2022 | 05/23/2022 | 10-Q |
| 12/31/2021 | 02/10/2022 | 10-Q |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 09/02/2021 | 10-K |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/04/2021 | 10-Q |
| 09/30/2020 | 11/10/2020 | 10-Q |
| 06/30/2020 | 09/09/2020 | 10-K |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/06/2020 | 10-Q |
| 09/30/2019 | 11/07/2019 | 10-Q |
| 06/30/2019 | 08/28/2019 | 10-K |
Recent Forward Guidance
Updated 6/1/2026Latest: Q3 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Share Repurchases | 25.00 Mil | 0 | Affirmed | Guidance: 25.00 Mil for 2026 | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/24/2026